Dcpp2 Inhibitors
Chemical inhibitors of Dcpp2 function primarily through the disruption of cell cycle progression and transcription regulation. Compounds like Palbociclib, Ribociclib, and Abemaciclib specifically target cyclin-dependent kinases CDK4 and CDK6. These kinases are crucial for the transition from the G1 phase to the S phase of the cell cycle, a process that is integral for cell proliferation. By inhibiting these kinases, these chemical agents arrest cells in the G1 phase, thereby indirectly limiting the activity of Dcpp2 by reducing the number of cells that enter the S phase where Dcpp2 activity is more prominent. Similarly, PD 0332991, which is synonymous with Palbociclib, exhibits the same mode of action, resulting in a comparable outcome on Dcpp2 activity.
In addition to these specific inhibitors, broader spectrum CDK inhibitors like Alsterpaullone, Roscovitine, Dinaciclib, Flavopiridol, Milciclib, SNS-032, and AZD5438 also modulate Dcpp2 activity but through a slightly different mechanism. These compounds inhibit a range of CDKs including CDK1, CDK2, CDK5, CDK7, and CDK9, which are involved not only in cell cycle control but also in transcriptional regulation. The inhibition of these kinases leads to a halt in cell cycle progression at various checkpoints and a decrease in transcriptional activity. As Dcpp2 is implicated in processes downstream of these events, such as DNA synthesis and gene expression, the reduction in kinase activity culminates in a decrease in the functional presence of Dcpp2 in the cell. By curtailing the fundamental processes necessary for Dcpp2 activity, these chemical inhibitors can indirectly modulate the protein's activity without directly interacting with it.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib directly inhibits cyclin-dependent kinases CDK4 and CDK6. Since these kinases are essential for the G1/S transition in the cell cycle, their inhibition leads to cell cycle arrest, thereby limiting the cellular context for Dcpp2 activity as Dcpp2 is involved in processes that are downstream of these checkpoints. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone targets and inhibits several cyclin-dependent kinases (CDKs), including CDK1, CDK2, and CDK5, as well as glycogen synthase kinase 3 beta (GSK-3β). By inhibiting these kinases, alsterpaullone disrupts cellular division and regulation, which indirectly limits the activity of Dcpp2 due to reduced kinase activity that would otherwise modulate its function. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine acts as an inhibitor for CDKs like CDK2, CDK7, and CDK9, which are involved in the regulation of transcription and cell cycle progression. By inhibiting these kinases, Roscovitine causes a decrease in cellular proliferation and transcriptional activity, indirectly leading to a decrease in Dcpp2 activity as it is dependent on these processes. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib specifically inhibits CDK4 and CDK6, which are integral to cell cycle progression. By halting the cell cycle, Ribociclib indirectly reduces the activity of Dcpp2, which is implicated in processes that occur downstream of CDK4/6 activity, such as DNA replication and cell division. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib selectively inhibits CDK4 and CDK6, leading to G1 phase arrest in the cell cycle. This inhibition results in reduced cellular proliferation, which in turn results in decreased functional activity of Dcpp2, as it is associated with proliferative processes. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib robustly inhibits CDKs, including CDK1, CDK2, CDK5, and CDK9. This broad inhibition of CDK activity results in cell cycle arrest and impaired transcription, which indirectly leads to a reduction in the functional activity of Dcpp2, due to the dependence of Dcpp2 activity on cellular proliferation and gene expression. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits various CDKs, particularly CDK9, which is involved in transcription. The inhibition of transcriptional elongation indirectly diminishes the activity of Dcpp2 by reducing the transcription of genes that are essential for the cellular processes in which Dcpp2 is involved. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib targets multiple CDKs and inhibits their activity. By doing so, it can cause cell cycle arrest and inhibit transcription, indirectly reducing the functional activity of Dcpp2 which is involved in downstream processes of these kinases. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a potent inhibitor of CDK2, CDK7, and CDK9, leading to cell cycle arrest and suppression of transcription. This reduces the number of cells progressing through the cycle and decreases overall transcription, indirectly reducing Dcpp2 activity that is related to these cellular functions. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 inhibits CDK1, CDK2, and CDK9, which leads to cell cycle arrest and the downregulation of transcription. This broad-spectrum inhibition of key cell cycle and transcription regulators indirectly results in the functional inhibition of Dcpp2 by limiting the cellular context where it would be active | ||||||